These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 24014343)

  • 21. Saxagliptin, alogliptin, and cardiovascular outcomes.
    Scirica BM; Braunwald E; Bhatt DL
    N Engl J Med; 2014 Jan; 370(5):483-4. PubMed ID: 24476444
    [No Abstract]   [Full Text] [Related]  

  • 22. Saxagliptin demonstrates no increased risk for cardiovascular death, heart attack or stroke in the SAVOR cardiovascular outcomes trial.
    Hardy G
    Cardiovasc J Afr; 2013 Aug; 24(7):290. PubMed ID: 24217308
    [No Abstract]   [Full Text] [Related]  

  • 23. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
    Deacon CF
    Curr Opin Investig Drugs; 2008 Apr; 9(4):402-13. PubMed ID: 18393107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy.
    Argyrakopoulou G; Doupis J
    Adv Ther; 2009 Mar; 26(3):272-80. PubMed ID: 19259628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment.
    Davis TM
    Diabetes Obes Metab; 2014 Oct; 16(10):891-9. PubMed ID: 24684351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes.
    Borja-Hart NL; Whalen KL
    Ann Pharmacother; 2010 Jun; 44(6):1046-53. PubMed ID: 20460554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDA approves saxagliptin for type 2 diabetes.
    Traynor K
    Am J Health Syst Pharm; 2009 Sep; 66(17):1513. PubMed ID: 19710429
    [No Abstract]   [Full Text] [Related]  

  • 28. [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
    Gallwitz B
    Pharm Unserer Zeit; 2010 Mar; 39(2):114-8. PubMed ID: 20196038
    [No Abstract]   [Full Text] [Related]  

  • 29. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Gallwitz B
    IDrugs; 2008 Dec; 11(12):906-17. PubMed ID: 19051153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In AF or VTE, warfarin dosing by genotype improved time in therapeutic range but not clinical outcomes.
    Dunn A
    Ann Intern Med; 2014 Mar; 160(6):JC9. PubMed ID: 24638187
    [No Abstract]   [Full Text] [Related]  

  • 31. ACP Journal Club. In at-risk patients with type 2 diabetes, saxagliptin and placebo did not differ for CV events.
    Morey-Vargas OL; Montori VM
    Ann Intern Med; 2014 Jan; 160(2):JC8-9. PubMed ID: 24445719
    [No Abstract]   [Full Text] [Related]  

  • 32. Choosing among the incretin agents and why it matters.
    Unger J
    J Fam Pract; 2010 May; 59(5 Suppl):S30-5. PubMed ID: 20544056
    [No Abstract]   [Full Text] [Related]  

  • 33. Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies.
    Schwartz SL
    Ann Med; 2012 Mar; 44(2):157-69. PubMed ID: 22132773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The physiologic role of incretin hormones: clinical applications.
    Cefalu WT
    J Am Osteopath Assoc; 2010 Mar; 110(3 Suppl 2):S8-S14. PubMed ID: 20382839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Commentary.
    Mahler RJ
    Diabetes Metab Res Rev; 2013 Jul; 29(5):427-8. PubMed ID: 23832427
    [No Abstract]   [Full Text] [Related]  

  • 36. Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials.
    Dicembrini I; Nreu B; Montereggi C; Mannucci E; Monami M
    Acta Diabetol; 2020 Jun; 57(6):689-696. PubMed ID: 31955260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.
    Asakawa T; Moritoh Y; Kataoka O; Suzuki N; Takeuchi K; Odaka H
    Life Sci; 2009 Jul; 85(3-4):122-6. PubMed ID: 19427871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
    Scheen AJ
    Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Baseline differences in the SAVOR trial.
    Luijendijk HJ; Hulshof TA
    Diabetes Obes Metab; 2015 Dec; 17(12):1202. PubMed ID: 26094750
    [No Abstract]   [Full Text] [Related]  

  • 40. Saxagliptin, alogliptin, and cardiovascular outcomes.
    White WB; Zannad F
    N Engl J Med; 2014 Jan; 370(5):484. PubMed ID: 24482824
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.